Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.
Novo Nordisk, the first company to develop a GLP-1 weight-loss drug, may soon surpass Eli Lilly in this emerging market. Initially designed for diabetics, the GLP-1 drug, under the brand names Wegovy and Ozempic, has gained popularity beyond its intended audience due to its weight-loss benefits. Novo Nordisk struggled to meet the high demand for their product, opening the door for Eli Lilly, which launched its own GLP-1 shot, Mounjaro and Zepbound, shortly after.
Despite Eli Lilly's early lead in the weight-loss sector, the tides are now turning in Novo Nordisk's favor. Their drug appears to be as effective as Eli Lilly's, giving the former a potential advantage in the competitive market.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
